Company Monitoring Page for Novartis

latest headlines for company on cafepharma

Novartis Calls for FDA Enforcement Against Biosimilar Misinformation
RAPS.org
Thu, 11/15/18 - 11:42 pm
Tags:
Novartis, FDA, biosimilars, citizen petitions
Novartis 'completely committed' to Sandoz, has no split-off plan
Yahoo/Reuters
Thu, 11/15/18 - 11:20 am
Tags:
Novartis, Sandoz, generics
Novartis files for Alcon spinoff, citing aging population and developing countries as top growth prospects
Fierce Pharma
Wed, 11/14/18 - 11:57 am
Tags:
Novartis, Alcon, spinoffs, SEC, eye health
Ionis, Akcea succeed in heart drug trial, setting up Novartis decision
Biopharma Dive
Tue, 11/13/18 - 10:13 pm
Tags:
Akcea Therapeutics, Ionis Pharmaceuticals, clinical trials, Novartis, AKCEA-APO(a)-Lrx
Novartis builds its blockbuster case for Entresto, beating out a cheap ACE inhibitor in a head-to-head study
Endpoints
Mon, 11/12/18 - 11:49 pm
Tags:
Novartis, Entresto
As Novartis' other cancer launches struggle, Lutathera gets off to flying start
Fierce Pharma
Fri, 11/9/18 - 11:43 am
Tags:
Novartis, Lutathera, drug launches, neuroendocrine tumors
Novartis Plans for 60 Regulatory Filings Over the Next Three Years
BioSpace
Tue, 11/6/18 - 09:41 am
Tags:
Novartis, drug development, R&D
Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
Endpoints
Tue, 11/6/18 - 12:27 am
Tags:
Novartis, drug pricing, AVXS-101, spinal muscular atrophy
Novartis' Sandoz calls it quits on Rituxan biosimilar after FDA requests more data
Fierce Pharma
Mon, 11/5/18 - 11:53 am
Tags:
Novartis, Sandoz, FDA, biosimilars, Roche, Rituxan
Novartis abandons effort for U.S. approval of biosimilar rituximab
Yahoo/Reuters
Sat, 11/3/18 - 12:39 pm
Tags:
Novartis, Sandoz, rituximab, biosimilars, Roche
NASH Treatment: Will a Combo Drug Developed by Novartis and Pfizer Make the Cut?
Xtalks
Thu, 11/1/18 - 07:13 pm
Tags:
Pfizer, Novartis, NASH
Novartis wins US nod for Humira biosimilar, but focus now on Europe
Biopharma Dive
Wed, 10/31/18 - 07:09 pm
Tags:
Novartis, Hyrimoz, biosimilars, Humira, AbbVie, FDA
Novartis May Beat Ironwood Pharmaceuticals to the Punch
Motley Fool
Tue, 10/30/18 - 11:17 pm
Tags:
Novartis, crizanlizumab, sickle cell disease, Ironwood Pharmaceuticals, IW-1701
Novartis Cuts 20% of Drug-Research Projects After Review
Bloomberg
Tue, 10/30/18 - 12:12 pm
Tags:
Novartis, R&D, drug development
Big Pharma rivals Pfizer and Novartis team up on NASH combo targets
Fierce Biotech
Mon, 10/29/18 - 11:50 am
Tags:
Pfizer, Novartis, NASH, drug development
Roche expands its PhIII program for Eylea rival as long-acting data back its blockbuster contender faricimab
Endpoints
Mon, 10/29/18 - 10:27 am
Tags:
Roche, Genentech, Regeneron, Novartis, Eylea, faricimab, wet-AMD
This Big Pharma Bet Isn't Paying Off Yet
Motley Fool
Sun, 10/28/18 - 07:42 pm
Tags:
Big Pharma, biosimilars, Novartis, Amgen, Merck, Pfizer, Biogen
Endocyte deal showcases Novartis' complex manufacturing juggling act
Biopharma Dive
Thu, 10/25/18 - 11:25 pm
Tags:
Novartis, Endocyte, earnings, drug manufacturing
FDA Grants Priority Review for Ruxolitinib (Jakafi) for Acute Graft-Versus-Host Disease
CP Wire
Thu, 10/25/18 - 09:52 am
Tags:
FDA, Incyte, Novartis, Jakavi, Jakafi, graft vs host disease
Thu, 10/25/18 - 09:33 am
Tags:
Incyte, graft vs host disease, Novartis, Jakafi

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.